Health is not only the cornerstone of personal quality of life, but also an important factor for social stability and economic development. Today, with the improvement of living standards and the enhancement of health awareness, people's concern for health issues has reached an unprecedented height.

Facing this global trend, numerous enterprises have actively engaged in the health industry, dedicating themselves to enhancing the quality and efficiency of medical services through technological innovation to meet the growing health demands of people.

In this context, BGI Genomics (300676.SZ) has stood out by its outstanding performance in the integration of technological innovation and precision medical care. Recently, at the '9th•Gelonghui•Global Investment Carnival•2025', it was awarded the 'Annual Excellent Health Enterprise'.

Among the many enterprises, why has BGI Genomics been able to distinguish itself?

Comprehensive product layout to meet diversified health market demands.

As one of the few companies in China and even globally that cover the entire industry chain and all application areas of genetics technology, BGI Genomics has a wide and in-depth business sector, covering five key areas including reproductive health, tumor prevention and control, and chronic disease management, fully reflecting the company's profound understanding of market demands.

By providing customized genetic testing services to different population groups, BGI Genomics has successfully met the diverse health testing needs in the market. This is evident from the widespread popularity of its products in the market and its strong brand influence.

Upon further observation of BGI Genomics' actual performance, we can find that the company's continuous growth and market recognition have been fully reflected in its latest financial data, further confirming its comprehensive layout and deep cultivation in the field of genetic technology.

The financial report shows that in terms of reproductive health business, the company achieved nearly 0.9 billion yuan in revenue in the first three quarters of 2024, a year-on-year growth of about 3.7%. The high revenue figures are sufficient to reflect the competitiveness of its products in the market.

In the primary prevention business, carrier screening test revenue increased by about 27% year-on-year, indicating significant progress in the company's preventive health services. In the secondary prevention business, non-invasive prenatal testing revenue remained stable, demonstrating the stability and maturity of the company's core product operation. At the same time, revenue from chromosomal abnormality testing (CNV-seq) also increased by about 22% year-on-year. In the tertiary prevention business, revenue from newborn genetic disease gene screening increased by about 38% year-on-year, and revenue from genetic disease gene testing for assisting clinical diagnosis of hereditary diseases increased by about 35%.

In the field of tumor and chronic disease prevention and control business, the company also performed well, achieving revenue of nearly 0.4 billion yuan in the first three quarters of 2024, a year-on-year growth of about 14.1%.

This growth is mainly due to two factors: first, driven by the policy guidance of the 'Healthy China Action - Cancer Prevention and Control Action Plan (2023-2030)', the significant increase in colorectal cancer screening projects targeting the general age-appropriate population in various regions has propelled the company's revenue from colorectal cancer testing in the first three quarters of this year to exceed one billion yuan, a year-on-year growth of about 126%. Second, benefiting from the increased public awareness of the genetic risk of tumors and the promotion of the significance of testing for somatic variation in guiding tumor treatment, revenue from genetic tumor gene testing increased by about 35% year-on-year.

It is not difficult to see that BGI Genomics' comprehensive product layout can provide customized genetic testing services for different populations, meeting the urgent market demand for diversified health solutions, enabling it to stand out from numerous enterprises.

AI empowerment leads precise medical care towards a new future.

Looking at the development trend of the entire industry, with rapid technological advancements, AI technology has become an important force driving social progress, demonstrating revolutionary potential in the field of life and health. Especially in the frontier field of genomic medicine, the application of AI is opening up new possibilities, injecting new vitality into the development of precision medicine.

In this big environment, bgi genomics has successfully integrated AI technology into genetic testing, leading precision medical into the next stage of development.

For example, at the 26th China International High-Tech Achievements Fair, bgi genomics showcased multiple innovative achievements, attracting wide attention in the industry, undoubtedly proving its leading position in intelligent services and cutting-edge technology.

The company's self-developed Generative Biology Intelligence innovative paradigm (GBI ALL) integrates the company's core technologies, including GeneT, a gene testing multimodal large model for clinical use, the ChatGeneT gene consultation platform for the public, and the intelligent disease prevention and control system '13311i', demonstrating AI's huge potential in improving the efficiency and quality of medical services.

Image: iGeneT Pro Intelligent Clinical Genetic Testing Solution

In addition, this year bgi genomics also launched two major AI+ one-stop solutions, which can provide a one-stop service from 'sample in' to 'result out', setting a new benchmark for the entire industry.

In June, bgi genomics' Geline Lingxi - AI+ one-stop NGS laboratory overall solution officially debuted. This solution, with its unique '331' design concept - '3-piece instrument set + AI 3 modules + 1 set of mixed sample rules software', simplifies and intelligently automates the complex experimental process of high-throughput sequencing.

Following that, at the 19th International Genomics Conference in November, bgi genomics introduced the BGI SIRO-16 Lingxi AI+ one-stop integrated solution, which adopts a highly integrated all-in-one machine model centered around AI, integrating the four core advantages of 'aggregation', 'intelligence', 'simplicity', and 'accuracy', achieving full-process automation of pathogenic microorganism gene testing.

Image: BGI SIRO-16 Lingxi AI+ one-stop comprehensive solution

Summary

As mentioned earlier, the achievements of bgi genomics can be attributed to its comprehensive product layout and relentless pursuit of technological innovation. As the company continues to integrate emerging technologies such as AI into its business development, we have reason to believe that bgi genomics will undoubtedly play an increasingly important role in the global health industry.

Therefore, the recognition of bgi genomics as the 'Annual Excellent Health Enterprise' award is not only a recognition of the company's past achievements, but also an acknowledgment of its potential for future development in the field of big health.